In the current study, the VEGF levels were reduced in both groups after treatment, with significantly lower levels in the study group than in the control group (P < 0.05), which was similar to the findings of Sadahiro et al. [22], suggesting that bevacizumab and gemcitabine combined with cisplatin for esophageal cancer could reduce VEGF levels and promote apoptosis of cancer cells. This evidence concerns the gene VEGFA and cancer.